Tag : neurological disorder

Clinical Research, Pharma & Healthcare Financing

BMS Shows Positive Data for Breyanzi in Marginal Zone Lymphoma

Business Wire
by Business Wire076
95.5% of patients with relapsed or refractory marginal zone lymphoma (MZL) treated with lisocabtagene maraleucel (liso-cel) achieved a response, with 62.1% achieving complete response and 88.6%...
Clinical Research, Pharma & Healthcare Financing

XellSmart’s iPSC Therapy for Spinal Injury Approved for FDA Trial

PR Newswire
by PR Newswire0102
In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic iPSC-derived subtype-specific neural regenerative cell therapy has received official approval from both China’s National...